Tirzepatide, the first dual agonist for the treatment of T2DM and obesity targeting GIPR and GLP-1R, was approved by the U.S. FDA in 2022. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.